{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:32:14Z","timestamp":1792751534810,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40263-026-01313-9","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:11:54Z","timestamp":1784023914000},"page":"1317-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Therapies for Angelman Syndrome"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7520-4788","authenticated-orcid":false,"given":"Cyril","family":"Tychon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Markati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Vanden","family":"Brande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"1313_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/ejhg.2014.93","volume":"23","author":"K Buiting","year":"2015","unstructured":"Buiting K, Clayton-Smith J, Driscoll DJ, Gillessen-Kaesbach G, Kanber D, Schwinger E, et al. Clinical utility gene card for: Angelman syndrome. Eur J Hum Genet. 2015;23:3\u20133. https:\/\/doi.org\/10.1038\/ejhg.2014.93.","journal-title":"Eur J Hum Genet"},{"key":"1313_CR2","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.jval.2023.09.1073","volume":"26","author":"M Arregui Rementeria","year":"2023","unstructured":"Arregui Rementeria M, Cadarette S, Oladapo T, Wissinger E, Ruiz K, Kistler K. EPH31 systematic literature review on the global epidemiology of Angelman syndrome. Value Health. 2023;26:S208\u2013S208.","journal-title":"Value Health"},{"key":"1313_CR3","doi-asserted-by":"publisher","unstructured":"Aquino NH, Bastos E, Fonseca LC, Llerena JC. Angelman syndrome methylation screening of 15q11-q13 in institutionalized individuals with severe mental retardation. Genet Test. Mary Ann Liebert, Inc.; 2002;6:129\u201331. https:\/\/doi.org\/10.1089\/10906570260199393","DOI":"10.1089\/10906570260199393"},{"key":"1313_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ajmg.1320380114","volume":"38","author":"JS Fryburg","year":"1991","unstructured":"Fryburg JS, Breg WR, Lindgren V. Diagnosis of Angelman syndrome in infants. Am J Med Genet. 1991;38:58\u201364. https:\/\/doi.org\/10.1002\/ajmg.1320380114.","journal-title":"Am J Med Genet"},{"key":"1313_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/GIM.0b013e3181def138","volume":"12","author":"CA Williams","year":"2010","unstructured":"Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet Med. 2010;12:385\u201395. https:\/\/doi.org\/10.1097\/GIM.0b013e3181def138.","journal-title":"Genet Med"},{"key":"1313_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajmg.a.36864","volume":"167","author":"AM Larson","year":"2015","unstructured":"Larson AM, Shinnick JE, Shaaya EA, Thiele EA, Thibert RL. Angelman syndrome in adulthood. Am J Med Genet A. 2015;167:331\u201344. https:\/\/doi.org\/10.1002\/ajmg.a.36864.","journal-title":"Am J Med Genet A"},{"key":"1313_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000328837","volume":"2","author":"A Dagli","year":"2011","unstructured":"Dagli A, Buiting K, Williams CA. Molecular and clinical aspects of Angelman syndrome. Mol Syndromol. 2011;2:100\u201312. https:\/\/doi.org\/10.1159\/000328837.","journal-title":"Mol Syndromol"},{"key":"1313_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.braindev.2020.08.014","volume":"43","author":"D Samanta","year":"2021","unstructured":"Samanta D. Epilepsy in Angelman syndrome: a scoping review. Brain Dev. 2021;43:32\u201344. https:\/\/doi.org\/10.1016\/j.braindev.2020.08.014.","journal-title":"Brain Dev"},{"key":"1313_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1824-7288-36-31","volume":"36","author":"A Fiumara","year":"2010","unstructured":"Fiumara A, Pittal\u00e0 A, Cocuzza M, Sorge G. Epilepsy in patients with Angelman syndrome. Ital J Pediatr. 2010;36:31. https:\/\/doi.org\/10.1186\/1824-7288-36-31.","journal-title":"Ital J Pediatr"},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ng0997-14","volume":"17","author":"C Rougeulle","year":"1997","unstructured":"Rougeulle C, Glatt H, Lalande M. The Angelman syndrome candidate gene, UBE3A\/E6-AP, is imprinted in brain. Nat Genet. 1997;17:14\u20135. https:\/\/doi.org\/10.1038\/ng0997-14.","journal-title":"Nat Genet"},{"key":"1313_CR11","doi-asserted-by":"publisher","unstructured":"Bird L. Angelman syndrome: review of clinical and molecular aspects. Appl Clin Genet. 2014 May 16;7:93\u2013104. https:\/\/doi.org\/10.2147\/TACG.S57386","DOI":"10.2147\/TACG.S57386"},{"key":"1313_CR12","doi-asserted-by":"publisher","unstructured":"Germain ND, Gorka D, Drennan R, Jafar-nejad P, Whipple A, Core L, Levine ES, Rigo F, Chamberlain SJ. Antisense oligonucleotides targeting UBE3A-ATS restore expression of UBE3A by relieving transcriptional interference [Internet]. bioRxiv; 2021 [cited 2025 July 10]. p. 2021.07.09.451826. https:\/\/doi.org\/10.1101\/2021.07.09.451826","DOI":"10.1101\/2021.07.09.451826"},{"key":"1313_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2024.1410791","volume":"18","author":"C Gonzalez Ramirez","year":"2024","unstructured":"Gonzalez Ramirez C, Salvador SG, Patel RKR, Clark S, Miller NW, James LM, et al. Regional and cellular organization of the autism-associated protein UBE3A\/E6AP and its antisense transcript in the brain of the developing rhesus monkey. Front Neuroanat. 2024;18:1410791. https:\/\/doi.org\/10.3389\/fnana.2024.1410791.","journal-title":"Front Neuroanat"},{"key":"1313_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/jmg.2005.036913","volume":"43","author":"T Sahoo","year":"2006","unstructured":"Sahoo T, Peters SU, Madduri NS, Glaze DG, German JR, Bird LM, et al. Microarray based comparative genomic hybridization testing in deletion bearing patients with Angelman syndrome: genotype-phenotype correlations. J Med Genet. 2006;43:512\u20136. https:\/\/doi.org\/10.1136\/jmg.2005.036913.","journal-title":"J Med Genet"},{"key":"1313_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/dmcn.14831","volume":"63","author":"Y Elgersma","year":"2021","unstructured":"Elgersma Y, Sonzogni M. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome. Dev Med Child Neurol. 2021;63:802\u20137. https:\/\/doi.org\/10.1111\/dmcn.14831.","journal-title":"Dev Med Child Neurol"},{"key":"1313_CR16","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1038\/s41380-020-0858-6","volume":"26","author":"M Keute","year":"2021","unstructured":"Keute M, Miller MT, Krishnan ML, Sadhwani A, Chamberlain S, Thibert RL, et al. Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Mol Psychiatry. 2021;26:3625\u201333. https:\/\/doi.org\/10.1038\/s41380-020-0858-6.","journal-title":"Mol Psychiatry"},{"key":"1313_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-017-0500-x","volume":"18","author":"C Aguilera","year":"2017","unstructured":"Aguilera C, Vi\u00f1as-Jornet M, Baena N, Gabau E, Fern\u00e1ndez C, Capdevila N, et al. Novel intragenic deletions within the UBE3A gene in two unrelated patients with Angelman syndrome: case report and review of the literature. BMC Med Genet. 2017;18:137. https:\/\/doi.org\/10.1186\/s12881-017-0500-x.","journal-title":"BMC Med Genet"},{"key":"1313_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/genes12070987","volume":"12","author":"L Yang","year":"2021","unstructured":"Yang L, Shu X, Mao S, Wang Y, Du X, Zou C. Genotype\u2013phenotype correlations in Angelman syndrome. Genes (Basel). 2021;12:987. https:\/\/doi.org\/10.3390\/genes12070987.","journal-title":"Genes (Basel)"},{"key":"1313_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13023-017-0716-z","volume":"12","author":"AC Wheeler","year":"2017","unstructured":"Wheeler AC, Sacco P, Cabo R. Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis. 2017;12:164. https:\/\/doi.org\/10.1186\/s13023-017-0716-z.","journal-title":"Orphanet J Rare Dis"},{"key":"1313_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00476","volume":"11","author":"SJ Lopez","year":"2018","unstructured":"Lopez SJ, Segal DJ, LaSalle JM. UBE3A: an E3 ubiquitin ligase with genome-wide impact in neurodevelopmental disease. Front Mol Neurosci. 2018;11:476. https:\/\/doi.org\/10.3389\/fnmol.2018.00476.","journal-title":"Front Mol Neurosci"},{"key":"1313_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tins.2011.04.001","volume":"34","author":"AM Mabb","year":"2011","unstructured":"Mabb AM, Judson MC, Zylka MJ, Philpot BD. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 2011;34:293\u2013303. https:\/\/doi.org\/10.1016\/j.tins.2011.04.001.","journal-title":"Trends Neurosci"},{"key":"1313_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.02.040","volume":"90","author":"MC Judson","year":"2016","unstructured":"Judson MC, Wallace ML, Sidorov MS, Burette AC, Gu B, van Woerden GM, et al. GABAergic neuron-specific loss of Ube3a causes Angelman syndrome-like EEG abnormalities and enhances seizure susceptibility. Neuron. 2016;90:56\u201369. https:\/\/doi.org\/10.1016\/j.neuron.2016.02.040.","journal-title":"Neuron"},{"key":"1313_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neuroscience.2020.02.017","volume":"445","author":"DC Rotaru","year":"2020","unstructured":"Rotaru DC, Mientjes EJ, Elgersma Y. Angelman syndrome: from mouse models to therapy. Neuroscience. 2020;445:172\u201389. https:\/\/doi.org\/10.1016\/j.neuroscience.2020.02.017.","journal-title":"Neuroscience"},{"key":"1313_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neulet.2010.08.001","volume":"483","author":"WH Roden","year":"2010","unstructured":"Roden WH, Peugh LD, Jansen LA. Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex. Neurosci Lett. 2010;483:167\u201372. https:\/\/doi.org\/10.1016\/j.neulet.2010.08.001.","journal-title":"Neurosci Lett"},{"key":"1313_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107286","volume":"200","author":"PJ Fitzgerald","year":"2024","unstructured":"Fitzgerald PJ. Neural hyperexcitability in Angelman syndrome: genetic factors and pharmacologic treatment approaches. Epilepsy Res. 2024;200:107286. https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107286.","journal-title":"Epilepsy Res"},{"key":"1313_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1843","volume":"10","author":"J Duis","year":"2022","unstructured":"Duis J, Nespeca M, Summers J, Bird L, Bindels\u2010de Heus KGCB, Valstar MJ, et al. A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Mol Genet Genomic Med. 2022;10:e1843. https:\/\/doi.org\/10.1002\/mgg3.1843.","journal-title":"Mol Genet Genomic Med"},{"key":"1313_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pediatrneurol.2025.05.005","volume":"169","author":"D Walkowiak","year":"2025","unstructured":"Walkowiak D, Domaradzki J. Caregiving burden and quality of life among parents of individuals with Angelman syndrome: gender differences and the impact of financial well-being. Pediatr Neurol. 2025;169:31\u20139. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2025.05.005.","journal-title":"Pediatr Neurol"},{"key":"1313_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/13543784.2021.1939674","volume":"30","author":"T Markati","year":"2021","unstructured":"Markati T, Duis J, Servais L. Therapies in preclinical and clinical development for Angelman syndrome. Expert Opin Investig Drugs. 2021;30:709\u201320. https:\/\/doi.org\/10.1080\/13543784.2021.1939674.","journal-title":"Expert Opin Investig Drugs"},{"key":"1313_CR29","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/hmg\/dds130","volume":"21","author":"L Meng","year":"2012","unstructured":"Meng L, Person RE, Beaudet AL. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. Hum Mol Genet. 2012;21:3001\u201312. https:\/\/doi.org\/10.1093\/hmg\/dds130.","journal-title":"Hum Mol Genet"},{"key":"1313_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature10726","volume":"481","author":"H-S Huang","year":"2012","unstructured":"Huang H-S, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature. 2012;481:185\u20139. https:\/\/doi.org\/10.1038\/nature10726.","journal-title":"Nature"},{"key":"1313_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature13975","volume":"518","author":"L Meng","year":"2015","unstructured":"Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518:409\u201312. https:\/\/doi.org\/10.1038\/nature13975.","journal-title":"Nature"},{"key":"1313_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-025-00675-z","volume":"16","author":"C Milazzo","year":"2025","unstructured":"Milazzo C, Narayanan R, Badillo S, Wang S, Almand R, Monshouwer R, et al. UBE3A reinstatement restores behaviorand proteome in an Angelman syndrome mouse model of imprinting defects. Mol Autism. 2025;16:45. https:\/\/doi.org\/10.1186\/s13229-025-00675-z.","journal-title":"Mol Autism"},{"key":"1313_CR33","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.3390\/ijms26052304","volume":"26","author":"X Yang","year":"2025","unstructured":"Yang X, Huang Y-WA. Unraveling the roles of UBE3A in neurodevelopment and neurodegeneration. Int J Mol Sci. 2025;26:2304. https:\/\/doi.org\/10.3390\/ijms26052304.","journal-title":"Int J Mol Sci"},{"key":"1313_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tig.2010.05.007","volume":"26","author":"R Toro","year":"2010","unstructured":"Toro R, Konyukh M, Delorme R, Leblond C, Chaste P, Fauchereau F, et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010;26:363\u201372. https:\/\/doi.org\/10.1016\/j.tig.2010.05.007.","journal-title":"Trends Genet"},{"key":"1313_CR35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbrc.2015.06.171","volume":"464","author":"S-I Hori","year":"2015","unstructured":"Hori S-I, Yamamoto T, Obika S. XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides. Biochem Biophys Res Commun. 2015;464:506\u201311. https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.171.","journal-title":"Biochem Biophys Res Commun"},{"key":"1313_CR36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature03035","volume":"432","author":"S West","year":"2004","unstructured":"West S, Gromak N, Proudfoot NJ. Human 5\u2032\u00a0\u2192\u00a03\u2032 exonuclease Xrn2 promotes transcription termination at co-transcriptional cleavage sites. Nature. 2004;432:522\u20135. https:\/\/doi.org\/10.1038\/nature03035.","journal-title":"Nature"},{"key":"1313_CR37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.molcel.2019.12.029","volume":"77","author":"F Lai","year":"2020","unstructured":"Lai F, Damle SS, Ling KK, Rigo F. Directed RNase H cleavage of nascent transcripts causes transcription termination. Mol Cell. 2020;77:1032\u201343.e4. https:\/\/doi.org\/10.1016\/j.molcel.2019.12.029.","journal-title":"Mol Cell"},{"key":"1313_CR38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.molcel.2019.12.011","volume":"77","author":"J-S Lee","year":"2020","unstructured":"Lee J-S, Mendell JT. Antisense-mediated transcript knockdown triggers premature transcription termination. Mol Cell. 2020;77:1044\u201354.e3. https:\/\/doi.org\/10.1016\/j.molcel.2019.12.011.","journal-title":"Mol Cell"},{"key":"1313_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf4077","volume":"15","author":"SV Dindot","year":"2023","unstructured":"Dindot SV, Christian S, Murphy WJ, Berent A, Panagoulias J, Schlafer A, et al. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci Transl Med. 2023;15:eabf4077. https:\/\/doi.org\/10.1126\/scitranslmed.abf4077.","journal-title":"Sci Transl Med"},{"key":"1313_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145991","volume":"6","author":"C Milazzo","year":"2021","unstructured":"Milazzo C, Mientjes EJ, Wallaard I, Rasmussen SV, Erichsen KD, Kakunuri T, et al. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. JCI Insight. 2021;6:e145991. https:\/\/doi.org\/10.1172\/jci.insight.145991.","journal-title":"JCI Insight"},{"key":"1313_CR41","doi-asserted-by":"publisher","unstructured":"Jagasia R, Bon C, Rasmussen SV, Badillo S, Tehler D, Buchy D, et al. Angelman syndrome patient neuron screen identifies a potent and selective clinical ASO targeting UBE3A-ATS with long lasting effect in cynomolgus monkey [Internet]. 2022 [cited 2025 Jan 14]. https:\/\/doi.org\/10.1101\/2022.06.09.495066.","DOI":"10.1101\/2022.06.09.495066"},{"key":"1313_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142574","volume":"131","author":"RS Schmid","year":"2021","unstructured":"Schmid RS, Deng X, Panikker P, Msackyi M, Breton C, Wilson JM. CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. J Clin Invest. 2021;131:e142574. https:\/\/doi.org\/10.1172\/JCI142574.","journal-title":"J Clin Invest"},{"key":"1313_CR43","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2015.236","volume":"24","author":"BJ Bailus","year":"2016","unstructured":"Bailus BJ, Pyles B, McAlister MM, O\u2019Geen H, Lockwood SH, Adams AN, et al. Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an Angelman syndrome mouse brain. Mol Ther. 2016;24:548\u201355. https:\/\/doi.org\/10.1038\/mt.2015.236.","journal-title":"Mol Ther"},{"key":"1313_CR44","doi-asserted-by":"publisher","unstructured":"Daily JL, Nash K, Jinwal U, Golde T, Rogers J, Peters MM, et al. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. Burgess HA, editor. PLoS ONE. 2011;6:e27221. https:\/\/doi.org\/10.1371\/journal.pone.0027221.","DOI":"10.1371\/journal.pone.0027221"},{"key":"1313_CR45","unstructured":"MavriX Bio. MavriX bio announces FDA clearance of IND application to initiate first-in-human study of gene therapy for angelman syndrome [Internet]. Middleton (MA): PR Newswire; 2025 May 12 [cited 2025 Jul 10]. Available from: https:\/\/www.prnewswire.com\/news-releases\/mavrix-bio-announces-fda-clearance-of-ind-application-to-initiate-first-in-human-study-of-gene-therapy-for-angelman-syndrome-302451763.html."},{"key":"1313_CR46","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/hmg\/ddaa191","volume":"29","author":"CL Sirois","year":"2020","unstructured":"Sirois CL, Bloom JE, Fink JJ, Gorka D, Keller S, Germain ND, et al. Abundance and localization of human UBE3A protein isoforms. Hum Mol Genet. 2020;29:3021\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddaa191.","journal-title":"Hum Mol Genet"},{"key":"1313_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144712","volume":"6","author":"MC Judson","year":"2021","unstructured":"Judson MC, Shyng C, Simon JM, Davis CR, Punt AM, Salmon MT, et al. Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice. JCI Insight. 2021;6:e144712. https:\/\/doi.org\/10.1172\/jci.insight.144712.","journal-title":"JCI Insight"},{"key":"1313_CR48","doi-asserted-by":"crossref","unstructured":"Knee KM, Weeber EJ, Armstrong N, Stoub RE, Copping NA, Bailus BJ, et al. Rodent models and how they define potential human benefit: a translational review for Angelman syndrome [Internet]. FAST-DART E-Journal; 2025 Nov. Available from: https:\/\/cureangelman.org\/dart-review-rodent-models-human-benefit","DOI":"10.65856\/FFKJ4964"},{"key":"1313_CR49","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/hmg\/ddab104","volume":"30","author":"A Adhikari","year":"2021","unstructured":"Adhikari A, Copping NA, Beegle J, Cameron DL, Deng P, O\u2019Geen H, et al. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. Hum Mol Genet. 2021;30:1067\u201383. https:\/\/doi.org\/10.1093\/hmg\/ddab104.","journal-title":"Hum Mol Genet"},{"key":"1313_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/aur.2418","volume":"14","author":"E Cruz","year":"2021","unstructured":"Cruz E, Descalzi G, Steinmetz A, Scharfman HE, Katzman A, Alberini CM. CIM6P\/IGF-2 receptor ligands reverse deficits in Angelman syndrome model mice. Autism Res. 2021;14:29\u201345. https:\/\/doi.org\/10.1002\/aur.2418.","journal-title":"Autism Res"},{"key":"1313_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bbr.2010.02.039","volume":"210","author":"J Guan","year":"2010","unstructured":"Guan J, Zhang R, Dale-Gandar L, Hodgkinson S, Vickers MH. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010;210:221\u20138. https:\/\/doi.org\/10.1016\/j.bbr.2010.02.039.","journal-title":"Behav Brain Res"},{"key":"1313_CR52","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ymthe.2023.01.013","volume":"31","author":"H O\u2019Geen","year":"2023","unstructured":"O\u2019Geen H, Beitnere U, Garcia MS, Adhikari A, Cameron DL, Fenton TA, et al. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model. Mol Ther. 2023;31:1088\u2013105. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.013.","journal-title":"Mol Ther"},{"key":"1313_CR53","doi-asserted-by":"publisher","first-page":"i31","DOI":"10.1093\/ijnp\/pyae059.055","volume":"28","author":"MC Hernandez","year":"2025","unstructured":"Hernandez MC, Cecere G, Ballard TM, Honer M, Hipp JF, Knoflach F, et al. Preclinical evidence supporting the role of alogabat, a GABAa-a5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders. Int J Neuropsychopharmacol. 2025;28:i31\u20132. https:\/\/doi.org\/10.1093\/ijnp\/pyae059.055.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1313_CR54","unstructured":"An important update from Roche\/Genentech regarding the discontinuation of the alogabat program for Angelman syndrome. [Internet]. FAST. 2026 [cited 2026 June 3]. https:\/\/cureangelman.org. Accessed 3 June 2026."},{"key":"1313_CR55","unstructured":"Communique Ovid-1607005338.pdf [Internet]. [cited 2025 Aug 15]. https:\/\/www.angelman-afsa.org\/fichiers\/Communique%20Ovid%20-1607005338.pdf. Accessed 15 Aug 2025."},{"key":"1313_CR56","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41591-025-03784-7","volume":"31","author":"JF Hipp","year":"2025","unstructured":"Hipp JF, Bacino CA, Bird LM, Bruenig-Traebert I, Chan D, de Wit MC, et al. The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial. Nat Med. 2025;31:2936\u201345. https:\/\/doi.org\/10.1038\/s41591-025-03784-7.","journal-title":"Nat Med"},{"key":"1313_CR57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/dmd.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, et al. Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs. Drug Metab Dispos. 2022;50:879\u201387. https:\/\/doi.org\/10.1124\/dmd.121.000418.","journal-title":"Drug Metab Dispos"},{"key":"1313_CR58","unstructured":"Roche\u2019s Rugonersen Trials: Angelman Syndrome Update [Internet]. FAST. [cited 2025 June 17]. https:\/\/cureangelman.org. Accessed 17 June 2025."},{"key":"1313_CR59","unstructured":"Oak Hill Bio. Oak Hill Bio enters into exclusive license agreement with Roche to obtain global rights for a phase 3-ready, potential best-in-class treatment for individuals with Angelman syndrome [Internet]. Cambridge (MA): Business Wire; 2025 Apr 15. Available from: https:\/\/www.businesswire.com\/news\/home\/20250415795863\/en\/Oak-Hill-Bio-Enters-into-Exclusive-License-Agreement-with-Roche-to-Obtain-Global-Rights-for-a-Phase-3-Ready-Potential-Best-in-Class-Treatment-for-Individuals-with-Angelman-Syndrome."},{"key":"1313_CR60","unstructured":"Ultragenyx announces first patient dosed in aurora study evaluating GTX-102 in additional Angelman syndrome genotypes and age groups\u2014Ultragenyx Pharmaceutical Inc. [Internet]. [cited 2026 June 1]. https:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-announces-first-patient-dosed-aurora-study-evaluating. Accessed 1 June 2026."},{"key":"1313_CR61","unstructured":"Ultragenyx says Angelman therapy is working, but safety questions remain | BioPharma Dive [Internet]. [cited 2025 Aug 14]. https:\/\/www.biopharmadive.com\/news\/ultragenyx-angelman-gtx-102-interim-results\/713169\/. Accessed 14 Aug 2025."},{"key":"1313_CR62","unstructured":"New data on GTX-102 may support restart of Angelman phase 1\/2 trial [Internet]. 2021 [cited 2025 Aug 14]. https:\/\/angelmansyndromenews.com\/news\/gtx-102-data-genetx-ultragenyx-may-support-restart-phase-1-2-trial\/. Accessed 14 Aug 2025."},{"key":"1313_CR63","unstructured":"Goodspeed K, Brandabur M, Cimms T, Aquino P, Chen A, Tan W-H, Myers KA, Berry-Kravis E, Servais L, Sell E, Olugemo K. Updated clinical activity and safety from a phase 1\/2 open-label trial of GTX-102, an investigational antisense oligonucleotide for the treatment of patients with Angelman syndrome [abstract]. Ann Neurol. 2024;96(Suppl S33):S100-S101. Abstract nr PL3-1. Presented at the 53rd Child Neurology Society Annual Meeting; 2024 Nov 11\u201314; San Diego, CA."},{"key":"1313_CR64","unstructured":"Ultragenyx receives breakthrough therapy designation for GTX-102 in Angelman syndrome\u2014Ultragenyx Pharmaceutical Inc. [Internet]. [cited 2026 May 20]. https:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-receives-breakthrough-therapy-designation-gtx-102. Accessed 20 May 2026."},{"key":"1313_CR65","unstructured":"Berent A. A roadmap to a cure: accelerating drug development for Angelman syndrome [presentation\/video]. Presented at: 2024 FAST Global Summit on Angelman Syndrome; 2024 Nov 8; Orlando, FL. Available from: https:\/\/cureangelman.org\/articles\/2024-global-science-summit-recap"},{"key":"1313_CR66","unstructured":"REVEAL: a phase 3 study of ION582 in Angelman syndrome | Clinical research trial listing [Internet]. [cited 2026 May 20]. https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT06914609\/reveal-a-phase-3-study-of-ion582-in-angelman-syndrome\/reveal-a-phase-3-study-of-ion582-in-angelman-syndrome. Accessed 20 May 2026."},{"key":"1313_CR67","unstructured":"Ionis receives U.S. FDA breakthrough therapy designation for ION582 in Angelman syndrome | Ionis Pharmaceuticals, Inc. [Internet]. [cited 2026 May 20]. https:\/\/ir.ionis.com\/news-releases\/news-release-details\/ionis-receives-us-fda-breakthrough-therapy-designation-ion582. Accessed 20 May 2026."},{"key":"1313_CR68","unstructured":"Pharmaceuticals N. ASX:NEU-NNZ-2591 Angelman top-line results presentation [Internet]. Neuren Pharm. [cited 2026 May 20]. https:\/\/neurenpharma.com\/announcements\/6474317. Accessed 20 May 2026."},{"key":"1313_CR69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejpn.2023.07.008","volume":"47","author":"C Keary","year":"2023","unstructured":"Keary C, Bird LM, de Wit M-C, Hatti S, Heimer G, Heussler H, et al. Gaboxadol in Angelman syndrome: a double-blind, parallel-group, randomized placebo-controlled phase 3 study. Eur J Paediatr Neurol. 2023;47:6\u201312. https:\/\/doi.org\/10.1016\/j.ejpn.2023.07.008.","journal-title":"Eur J Paediatr Neurol"},{"key":"1313_CR70","unstructured":"PhD LS. Final trial data support Ovid\u2019s decision to stop OV101 program in 2021| Ovid licenses OV101 to Healx for testing in neurodegenerative diseases | Angelman Syndrome News [Internet]. 2023 [cited 2026 Jan 9]. https:\/\/angelmansyndromenews.com\/news\/final-trial-data-support-ovid-decision-stop-ov101-clinical\/. Accessed 9 Jan 2026."},{"key":"1313_CR71","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10578-020-01051-z","volume":"52","author":"T Willgoss","year":"2021","unstructured":"Willgoss T, Cassater D, Connor S, Krishnan ML, Miller MT, Dias-Barbosa C, et al. Measuring what matters to individuals with Angelman syndrome and their families: development of a patient-centered disease concept model. Child Psychiatry Hum Dev. 2021;52:654\u201368. https:\/\/doi.org\/10.1007\/s10578-020-01051-z.","journal-title":"Child Psychiatry Hum Dev"},{"key":"1313_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0551-7","volume":"12","author":"R Rodriguez-Monguio","year":"2017","unstructured":"Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients\u2019 health needs? Orphanet J Rare Dis. 2017;12:1. https:\/\/doi.org\/10.1186\/s13023-016-0551-7.","journal-title":"Orphanet J Rare Dis"},{"key":"1313_CR73","unstructured":"Allyson Berent (Roadmap) | 2024 FAST Global Summit on Angelman Syndrome [Internet]. 2024 [cited 2025 June 13]. https:\/\/www.youtube.com\/watch?v=Rqy2isijwoc. Accessed 13 June 2025."},{"key":"1313_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2022.101423","volume":"16","author":"SL Sansom","year":"2023","unstructured":"Sansom SL, Baker EK, Godler DE, Liew D. Estimating the impact of Angelman syndrome on parental productivity in Australia using productivity-adjusted life years. Disabil Health J. 2023;16:101423. https:\/\/doi.org\/10.1016\/j.dhjo.2022.101423.","journal-title":"Disabil Health J"},{"key":"1313_CR75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1352\/1944-7558-128.3.204","volume":"128","author":"CK Zigler","year":"2023","unstructured":"Zigler CK, Lin L, McFatrich M, Lucas N, Gordon KL, Jones HN, et al. Validation of the Observer-Reported Communication Ability (ORCA) measure for individuals with Angelman syndrome. Am J Intellect Dev Disabil. 2023;128:204\u201318. https:\/\/doi.org\/10.1352\/1944-7558-128.3.204.","journal-title":"Am J Intellect Dev Disabil"},{"key":"1313_CR76","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"key":"1313_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071377","volume":"14","author":"K Aragon-Gawinska","year":"2023","unstructured":"Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal muscular atrophy treatment in patients identified by newborn screening-a systematic review. Genes. 2023;14:1377. https:\/\/doi.org\/10.3390\/genes14071377.","journal-title":"Genes"},{"key":"1313_CR78","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1172\/JCI80554","volume":"125","author":"S Silva-Santos","year":"2015","unstructured":"Silva-Santos S, van Woerden GM, Bruinsma CF, Mientjes E, Jolfaei MA, Distel B, et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Investig. 2015;125:2069\u201376. https:\/\/doi.org\/10.1172\/JCI80554.","journal-title":"J Clin Investig"},{"key":"1313_CR79","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ymthe.2024.02.004","volume":"32","author":"MT Clarke","year":"2024","unstructured":"Clarke MT, Remesal L, Lentz L, Tan DJ, Young D, Thapa S, et al. Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice. Mol Ther. 2024;32:935\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.004.","journal-title":"Mol Ther"},{"key":"1313_CR80","doi-asserted-by":"publisher","unstructured":"Ferreira IR, Costa RA, Gomes LHF, dos Santos Cunha WD, Tyszler LS, Freitas S, et al. A newborn screening pilot study using methylation-sensitive high resolution melting on dried blood spots to detect Prader-Willi and Angelman syndromes. Sci Rep. 2020;10:13026. https:\/\/doi.org\/10.1038\/s41598-020-69750-0","DOI":"10.1038\/s41598-020-69750-0"},{"key":"1313_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101443","volume":"27","author":"T Minten","year":"2025","unstructured":"Minten T, Bick S, Adelson S, Gehlenborg N, Amendola LM, Boemer F, et al. Data-driven consideration of genetic disorders for global genomic newborn screening programs. Genet Med. 2025;27:101443. https:\/\/doi.org\/10.1016\/j.gim.2025.101443.","journal-title":"Genet Med"},{"key":"1313_CR82","unstructured":"Foundation for Angelman Syndrome Therapeutics (FAST). FAST-affiliated research program at UCLA is awarded $5.8M to advance gene therapy for Angelman syndrome [Internet]. Downers Grove (IL): FAST; 2025 Jan 30. Available from: https:\/\/cureangelman.org\/transformatx"},{"key":"1313_CR83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","volume":"587","author":"JM Wolter","year":"2020","unstructured":"Wolter JM, Mao H, Fragola G, Simon JM, Krantz JL, Bazick HO, et al. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature. 2020;587:281\u20134. https:\/\/doi.org\/10.1038\/s41586-020-2835-2.","journal-title":"Nature"},{"key":"1313_CR84","unstructured":"Encoded Therapeutics Inc. Encoded Therapeutics to Present New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting [Internet]. South San Francisco (CA): Business Wire; 2025 Apr 28. Available from: https:\/\/www.businesswire.com\/news\/home\/20250428852695\/en\/Encoded-Therapeutics-to-Present-New-Data-for-CNS-Gene-Therapy-Programs-at-the-ASGCT-28th-Annual-Meeting."},{"key":"1313_CR85","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1038\/s41467-024-49788-8","volume":"15","author":"H Vihma","year":"2024","unstructured":"Vihma H, Li K, Welton-Arndt A, Smith AL, Bettadapur KR, Gilmore RB, et al. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat Commun. 2024;15:5558. https:\/\/doi.org\/10.1038\/s41467-024-49788-8.","journal-title":"Nat Commun"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01313-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01313-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01313-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:59:57Z","timestamp":1789048797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01313-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":85,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01313-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CT was responsible for conducting the review, drafting the original manuscript, and performing revisions. TM was responsible for conducting the review, authoring, and reviewing the manuscript. SA and LVB contributed to the authoring and revision processes of the manuscript. LS was responsible for supervision and subsequent revisions of the manuscript.","order":2,"name":"Ethics","label":"Authors Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}